Loyal

About Loyal

Loyal is a company dedicated to helping dogs live longer and healthier lives by focusing on preventive care and addressing the underlying causes of age-associated diseases to delay their onset and reduce their impact.

Products & Services

LOY-002:A drug for senior dogs (age 10+, 14+ lb) focused on correcting metabolic dysfunction, with projected FDA approval in 2026.

LOY-002

Specialties

Dog Longevity Preventive Care Age-Associated Disease Treatment Metabolic Dysfunction Correction IGF-1 and Growth Hormone Regulation Canine longevity therapeutics Aging-related metabolic dysfunction treatment

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series C T: - FT: Series C	A: 100000000 MR: - FA: $100M FAN: 100000000	D: 2026-02-11 FD: 2026-02-11	2 investors

Series C Latest

2026-02-11

$100.0M

2 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

C

Celine Halioua

Founder & CEO

J

Jill Isenstadt

Chief Operating Officer

W

Wiwik Watanabe

Chief Technical Operations Officer

E

Ellen Ratcliff

VP, Clinical and Veterinary Medicine

M

Matt Peloquin

VP, Research

P

Phelps Peeler

VP, Product and Engineering

View 14 more team members with Pro

Unlock Full Team Directory

Recent News

Loyal Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised